Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313712 | 1.00 | HSD17B10 (0.32) | HSD17B10OPRK1CSF1RCYP2C9IDO1 | |
| SCHEMBL25316019 | 0.84 | CNR2 (0.33) | CYP2C9IDO1KCNH2 | |
| SCHEMBL25922588 | 0.84 | CNR2 (0.33) | CYP2C9IDO1KCNH2 | |
| SCHEMBL25316090 | 0.79 | GAA (0.40) | HSD17B10 | |
| SCHEMBL30507205 | 0.79 | GAA (0.40) | HSD17B10 | |
| SCHEMBL26024457 | 0.79 | GAA (0.40) | HSD17B10 | |
| SCHEMBL25922586 | 0.78 | IDO1 (0.34) | HSD17B10CYP2C9IDO1KCNH2 | |
| SCHEMBL31178329 | 0.77 | CYP1A2 (0.37) | HSD17B10CYP2C9 | |
| SCHEMBL25315214 | 0.77 | PDGFRB (0.33) | — | |
| SCHEMBL26023725 | 0.77 | PDGFRB (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | HSD17B10 1262/4885OPRK1 1495/4885CSF1R 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.